|
Synonyms: Example 5 [US383715659] | Jideytro® | NVL-520 | NVL520
zidesamtinib is an approved drug
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN zidesamtinib (a tyrosine kinase inhibitor that is intended as an antineoplastic agent). Zidesamtinib's structure matches that for the brain penetrant ROS1 inhibitor NVL-520, that was designed to overcome ROS1G2032R-mediated resistance to lorlatinib, entrectinib and crizotinib [1,4]. Objective tumour responses were observed in 3 patients with ROS1 mutation-positive lung cancers (including with brain metastases) that were resistant to other tyrosine kinase inhibitor therapies [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Nuvalent progressed NVL-520 to clinical evaluation, in patients with advanced/metastatic tumours with constitutively active (mutated) ROS1 tyrosine kinase. The US FDA approved zidesamtinib in July 2026 [3], to treat advanced/metastatic ROS1-positive non-small cell lung cancer in patients who have already been treated with a ROS1 inhibitor (e.g., lorlatinib, entrectinib, crizotinib). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05118789 | A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/Phase 2 Interventional | Nuvalent Inc. | The first-in-human ARROS-1 study | |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | Expanded Access | Nuvalent Inc. | ||